Pursuant to Regulations 30 and 33 of SEBI (LODR) Regulations, 2015, Mesco Pharmaceuticals has informed about submission of the Standalone unaudited Financial Results and Limited Review Report for the quarter ended on 31st December, 2018, duly considered and approved by the Board of Directors in their Board Meeting held on Wednesday, 13th February, 2019 at New Delhi commenced at 02:00 pm and concluded at 02:50 pm.
The above information is a part of company’s filings submitted to BSE.